Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy

Journal of Diabetes and its Complications

Volumn 23, Issue 3, 2009, Pages 178-184

  Higurashi, Mayumi ^a,b,c   Ohya, Yoshiyuki ^b   Joh, Kensuke ^b   Muraguchi, Masahiro ^d   Nishimura, Motonobu ^b   Terawaki, Hiroyuki ^b   Yagui, Kazuo ^a   Hashimoto, Naotake ^a   Saito, Yasushi ^a   Yamada, Kenichi ^b  

^a CHIBA UNIVERSITY   (Japan)

^b SAKURA NATIONAL HOSPITAL   (Japan)

^c The Japanese Association Clinic   (Singapore)

^d OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

CXC chemokine; Diabetic nephropathy; Inflammation

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CXCL9 CHEMOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERLEUKIN 8; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINARY EXCRETION; URINE LEVEL;

CHEMOKINE CXCL5; CHEMOKINE CXCL9; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED;

EID: 65249125831     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.12.001     Document Type: Article

References (36)

1. Baggiolini M., Dewald B., and Moser B. Human chemokines. An update. Annual Review of Immunology 15 (1997) 675-705
2. Carr M.E. Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and Its Complications 15 (2001) 44-54
3. Chen J., Gall M.A., Yokoyama H., Jensen J.S., Deckert M., and Parving H.H. Raised serum sialic acid concentrations in NIDDM patients with and without diabetic nephropathy. Diabetes Care 19 (1996) 130-134
4. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., and Tesch G.H. Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. Journal of the American Society of Nephrology 16 (2005) 1711-1722
5. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352 (1998) 213-219
6. Dalla Vestra M., Mussap M., Gallina P., Bruseghin M., Cernigoi A.M., Saller A., Plebani M., and Fioretto P. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. Journal of the American Society of Nephrology 16 (2005) S78-S82
7. Fridovich I. The biology of oxygen radicals. Science 201 (1978) 875-880
8. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., and Yoshinaga K. The role of macrophages in diabetic glomerulosclerosis. American Journal of Kidney Diseases 21 (1993) 480-485
9. Galkina E., and Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. Journal of the American Society of Nephrology 17 (2006) 368-377
10. Hirata K., Shikata K., Matsuda M., Akiyama K., Sugimoto H., Kushiro M., and Makino H. Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41 (1998) 185-192
11. Ihm C.G., Park J.K., Hong S.P., Lee T.W., Cho B.S., Kim M.J., Cha D.R., and Ha H. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79 (1998) 33-37
12. Kelly D.J., Chanty A., Gow R.M., Zhang Y., and Gilbert R.E. Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental nephropathy. Journal of the American Society of Nephrology 16 (2005) 1654-1660
13. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., Caorsi I., Vio C.P., Ruiz-Ortega M., and Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney International 64 Suppl 86 (2003) S64-S70
14. Navarro J.F., and Mora C. Role of inflammation in diabetic complications. Nephrol Dial Transplant 20 (2005) 2601-2604
15. Navarro J.F., Mora C., Macía M., and Garcia J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. American Journal of Kidney Diseases 42 (2003) 53-61
16. Navarro J.F., Mora C., Rivero A., Gallego E., Chahin J., Macia M., Méndez M.L., and Garcia J. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. American Journal of Kidney Diseases 33 (1999) 458-463
17. Ohmori M., Harada K., Kitoh Y., Nagasaka S., Saito T., and Fujimura A. The functions of circulatory polymorphonuclear leukocytes in diabetic patients with and without diabetic triopathy. Life sciences 66 (2000) 1861-1870
18. Olszyna D.P., Opal S.M., Prins J.M., Horn D.L., Speelman P., van Devennter S.J., and van del Poll T. Chemotactic activity of CXC chemokines interleukin-8, growth-related oncogene-α, and epithelial cell-derived neutrophil-activating protein-78 in urine of patients with urosepsis. The Journal of Infectious Diseases 182 (2000) 1731-1737
19. Omoto S., Nomura S., Shouzu A., Hayakawa T., Shimizu H., Miyake Y., Yonemoto T., Nishikawa M., Fukuhara S., and Inada M. Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 81 (1999) 271-277
20. Power C.A., Clemetson J.M., Clemetson K.J., and Wells T.N. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 7 (1995) 479-482
21. Romagnani P., Beltrame C., Annunziato F., Lasagni L., Luconi M., Galli G., Cosmi L., Maggi E., Salvadori M., Pupilli C., and Serio M. Role for interactions between IP-10/Mig and CXCR3 in proliferative glomerulonephritis. Journal of the American Society of Nephrology 10 (1999) 2518-2526
22. Romagnani P., Lazzeri E., Lasagni L., Mavilla C., Beltrame C., Francalanci M., Rotondi M., Annunziato F., Maurenzig L., Cosmi L., Galli G., Salvadori M., Maggi E., and Serio M. IP-10 and Mig production by glomerular cells in human proliferative glomerulonephritis and regulation by nitric oxide. Journal of the American Society of Nephrology 13 (2002) 53-64
23. Schlöndorff D., Nelson P.J., Luckow B., and Banas B. Chemokines and renal disease. Kidney International 51 (1997) 610-621
24. Schmid H., Boucherot A., Yasuda Y., Henger A., Brunner B., Eichinger F., Nitsche A., Kiss E., Bleich M., Gröne H.-J., Nelson P.J., Schlöndorff P.J., Cohen C.D., and Kretzler M. Modular activation of nuclear factor-κB transcriptional programs in human diabetic nephropathy. Diabetes 55 (2006) 2993-3003
25. Schmouder R.L., Strieter R.M., Walz A., and Kunkel S.L. Epithelial-derived neutrophil-activating factor-78 production in human renal tubule epithelial cells and in renal allograft rejection. Transplantation 59 (1995) 118-124
26. Schreiner G.F. The role of the macrophage in glomerular injury. Seminars in Nephrology 11 (1991) 268-275
27. Schwedler S., Schinzel R., Vaith P., and Wanner C. Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship?. Kidney International 59 Suppl 78 (2001) S32-S36
28. Segerer S., Nelson P.J., and Schlöndorff D. Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic studies. Journal of the American Society of Nephrology 11 (2000) 152-176
29. Segerer S., Banas B., Wöornle M., Schmid H., Cohen C.D., Kretzler M., Mack M., Kiss E., Nelson P.J., Schlöndorff D., and Gröne H.J. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. The American Journal of Pathology 164 (2004) 635-649
30. Takahashi T., Hato F., Yamane T., Inaba M., Okuno Y., Nishizawa Y., and Kitagawa S. Increased spontaneous adherence of neutrophils from type 2 diabetic patients with overt proteinuria. Diabetes Care 23 (2000) 417-418
31. Tuttle K.R. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. Journal of the American Society of Nephrology 16 (2005) 1537-1538
32. Tashiro K., Koyanagi I., Saitoh A., Shimizu A., Shike T., Ishiguro C., Koizumi M., Funabiki K., Horikoshi S., Shirato I., and Tomino Y. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and Interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. Journal of Clinical Laboratory Analysis 16 (2002) 1-4
33. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., Noronha I.L., and Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney International 63 (2003) 209-216
34. Walz A., Burgener R., Car B., Baggiolini M., Kunkel S.L., and Strieter R.M. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. The Journal of Experimental Medicine 174 (1991) 1355-1362
35. Wong C.K., Ho A.W., Tong P.C., Yeung C.Y., Kong A.P., Lun S.W., Chan J.C., and Lam C.W. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clinical and Experimental Immunology 149 (2007) 123-131
36. Young B.A., Johnson R.J., Alpers C.E., Eng E., Gordon K., Floege J., Couser W.G., and Seidel K. Cellular events in the evolution of experimental diabetic nephropathy. Kidney International 47 (1995) 935-944